SLIDES
1. Regeneus Investor Presentation
2. Disclaimer
3. Regeneus - company snapshot
4. Transformative Progenza™ OA deal with Kyocera
5. Company Overview and Market Opportunity
6. What is neuropathic pain?
7. Pain: A Growing Problem and Opportunity
8. Mesenchymal Stem Cells (MSCs)
9. Regeneus: Focus on Pain via Platform Technologies
10. Progenza™ OA & Current Treatment Market
11. Regeneus' Clinical Pipeline
12. Progenza™ Opportunity in Osteoarthritis (OA)
13. Competitive Allogeneic Clinical Landscape in Knee OA
14. Commercialisation Pathway & Outlook
15. Progenza™ OA Commercialisation Strategy
16. Collaboration and Licensing agreement with Kyocera
17. Upcoming Milestones
18. Investment Highlights
19. Thank you
Regeneus.pdf
1 / 19